Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.31 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | POLRMT | O00411 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25911789 | 0.97 | LMNA (0.32) | LMNAKMT2ARIPK1DOT1LCA12 | |
| SCHEMBL24917216 | 0.96 | LMNA (0.33) | LMNAKMT2ARIPK1DOT1LPOLRMT | |
| SCHEMBL25911813 | 0.93 | LMNA (0.39) | LMNAKMT2ARIPK1DOT1LPOLRMT | |
| SCHEMBL24789413 | 0.92 | CA12 (0.33) | LMNAKMT2ARIPK1CA12CA1 | |
| SCHEMBL24790490 | 0.91 | RIPK1 (0.33) | LMNAKMT2ARIPK1DOT1L | |
| SCHEMBL24917051 | 0.91 | LMNA (0.38) | LMNAKMT2ARIPK1POLRMT | |
| SCHEMBL24791010 | 0.90 | CA12 (0.33) | RIPK1CA12CA1CA2CA9 | |
| SCHEMBL25911782 | 0.90 | RIPK1 (0.33) | LMNAKMT2ARIPK1 | |
| SCHEMBL24791766 | 0.89 | RIPK1 (0.32) | LMNAKMT2ARIPK1 | |
| SCHEMBL25911664 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | LMNA 1629/4885KMT2A 3232/4885RIPK1 2571/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | LMNA 1629/4885KMT2A 3232/4885RIPK1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.